How complete is the portfolio data?: VC Dekho tracks portfolio companies mentioned in fund profiles and public deal coverage. Coverage is incomplete and skews toward funds and deals with public disclosure, not a full cap table view.
Can I search by sector instead of company name?: Not yet in this tool. Browse funds by sector or stage on the directory instead.
How is this different from the investor matcher?: The investor matcher ranks funds by your stage, sector, and cheque size. Portfolio lookup starts from a company you already know and shows which funds backed it, plus funds with similar portfolio patterns.
Does a listing mean the fund endorses my startup?: No. This only shows that a company appears in a fund's public portfolio or deal coverage. It is a research starting point, not an introduction or an endorsement.

Portfolio lookup

ICS 1st Floor

1 fund on VC Dekho list ICS 1st Floor in their portfolio.

1backing fund

Backing funds

Who backed ICS 1st Floor

Portfolio listing

Other startups sharing a backer, sector, or stage with ICS 1st Floor.

Widen the list

Funds that don't back ICS 1st Floor directly, but invest in similar sectors and stages.

Consumer / D2C

Consumer / D2C

Consumer / D2C

Consumer / D2C

Consumer / D2C

Consumer / D2C

FAQ

Coverage notes for ICS 1st Floor and how to widen your search.

How complete is the portfolio data?: VC Dekho tracks portfolio companies mentioned in fund profiles and public deal coverage. Coverage is incomplete and skews toward funds and deals with public disclosure, not a full cap table view.
Can I search by sector instead of company name?: Not yet in this tool. Browse funds by sector or stage on the directory instead.
How is this different from the investor matcher?: The investor matcher ranks funds by your stage, sector, and cheque size. Portfolio lookup starts from a company you already know and shows which funds backed it, plus funds with similar portfolio patterns.
Does a listing mean the fund endorses my startup?: No. This only shows that a company appears in a fund's public portfolio or deal coverage. It is a research starting point, not an introduction or an endorsement.